title: Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma.
abstract: Excessive elaboration of proinflammatory cytokines are involved in cachexia-related hypercatabolism. Parthenolide, as a potential anti-inflammatory active agent, could effectively inhibit nuclear factor-kappa B, and has the potential for the treatment of cancer cachexia. In this study, the cancer cachexia model was established by subcutaneous transplantation CT26 tumor fragment. Parthenolide or placebo was intraperitoneally given daily from the next day. Parthenolide treatment could effectively preserve the body weight, improve the mass of gastrocnemius and tibialis anterior muscles, and alleviate tumor burden. Sizes of muscle fibers and myosin heavy chain were also increasing. The serum proinflammatory cytokine TNF-α level was lower than placebo treatment mice measure by ELISA. To investigate the possible mechanism, MuRF1 and Fbx32 was subjected to Western blot analysis and expression of MURF1 was inhibited in gastrocnemius muscle. Collectively, parthenolide treatment could effectively alleviate tumor burden of cachexia, preserve the body weight and improve skeletal muscle characteristics.
authors.affiliation: Department of Pharmacy, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, PR China.
authors.forename: Quanjun
authors.initials: Q
authors.lastname: Yang
authors.forename: Lili
authors.initials: L
authors.lastname: Wan
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Zhou
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Qi
authors.initials: Q
authors.lastname: Yu
authors.forename: Liya
authors.initials: L
authors.lastname: Liu
authors.forename: Bin
authors.initials: B
authors.lastname: Li
authors.forename: Cheng
authors.initials: C
authors.lastname: Guo
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use; D019659:Asteraceae / Q000737:chemistry*; D001835:Body Weight / Q000187:drug effects; D002100:Cachexia / Q000378:metabolism / Q000517:prevention & control*; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009124:Muscle Proteins / Q000378:metabolism; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D009368:Neoplasm Transplantation; D009929:Organ Size / Q000187:drug effects; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D012717:Sesquiterpenes / Q000494:pharmacology / Q000627:therapeutic use*; D000070584:Tripartite Motif Proteins; D047368:Tumor Burden / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009124:Muscle Proteins; D010936:Plant Extracts; D012717:Sesquiterpenes; D000070584:Tripartite Motif Proteins; D014409:Tumor Necrosis Factor-alpha; C002669:parthenolide; C499084:Trim63 protein, mouse; D044767:Ubiquitin-Protein Ligases
keywords: Cancer cachexia; Parthenium integrifolium; Parthenolide; Skeletal muscle; Tumor burden